Literature DB >> 11382952

Evaluation of female intrapelvic tumors by clinical proton MR spectroscopy.

T Okada1, M Harada, K Matsuzaki, H Nishitani, T Aono.   

Abstract

We measured metabolites in large tumors of the female pelvis (23 cases total: 6 malignant cases, 17 benign cases) using single-voxel proton magnetic resonance (MR) spectroscopy and evaluated the clinical significance of this method in the differential diagnosis of female pelvic tumors. The characteristically obtained signal was lactate, which was detected not only in all the malignant tumors but also in some of the benign tumors. However, the lactate signals of the malignant tumors tended to form higher peaks than those of benign tumors, which was a finding consistent with the result of the earlier in vitro study reported in ovarian tumors. The signal of choline-containing compounds (Cho) was found only in solid tumors, and the signal intensity varied among different histological types of tumors, possibly reflecting metabolic activity of the cell membrane. We considered that proton MR spectroscopy (MRS) of intrapelvic tumors would be useful for the diagnosis of the nature of female intrapelvic tumors. J. Magn. Reson. Imaging 2001;13:912-917. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11382952     DOI: 10.1002/jmri.1130

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  10 in total

1.  Differentiation of benign and malignant uterine corpus tumors by using proton MR spectroscopy at 3T: preliminary study.

Authors:  Mayumi Takeuchi; Kenji Matsuzaki; Masafumi Harada
Journal:  Eur Radiol       Date:  2010-10-03       Impact factor: 5.315

2.  Preliminary observations and clinical value of N-acetyl resonances in ovarian tumours using in-vivo proton MR spectroscopy at 3T.

Authors:  Mayumi Takeuchi; Kenji Matsuzaki; Masafumi Harada
Journal:  Eur Radiol       Date:  2011-08-05       Impact factor: 5.315

Review 3.  Imaging ovarian cancer and peritoneal metastases--current and emerging techniques.

Authors:  Stavroula Kyriazi; Stan B Kaye; Nandita M deSouza
Journal:  Nat Rev Clin Oncol       Date:  2010-04-13       Impact factor: 66.675

Review 4.  Proton magnetic resonance spectroscopy in oncology: the fingerprints of cancer?

Authors:  Roberto García-Figueiras; Sandra Baleato-González; Anwar R Padhani; Laura Oleaga; Joan C Vilanova; Antonio Luna; Juan Carlos Cobas Gómez
Journal:  Diagn Interv Radiol       Date:  2016 Jan-Feb       Impact factor: 2.630

5.  Can magnetic resonance spectroscopy differentiate endometrial cancer?

Authors:  Jie Zhang; Shifeng Cai; Changzhong Li; Xichao Sun; Xue Han; Chunrun Yang; Caixia Fu; Qingwei Liu; Yinghui Xin; Yuanyuan Zong
Journal:  Eur Radiol       Date:  2014-06-06       Impact factor: 5.315

6.  Preliminary observations and clinical value of lipid peak in high-grade uterine sarcomas using in vivo proton MR spectroscopy.

Authors:  Mayumi Takeuchi; Kenji Matsuzaki; Masafumi Harada
Journal:  Eur Radiol       Date:  2013-06-06       Impact factor: 5.315

7.  Proton MR spectroscopy and the detection of malignancy in ovarian masses.

Authors:  Sahar Mahmoud Mansour; Mohammed Mohammed Mohammed Gomma; Peter Nashaat Shafik
Journal:  Br J Radiol       Date:  2019-07-18       Impact factor: 3.039

8.  Metabolomic Characterization of Ovarian Epithelial Carcinomas by HRMAS-NMR Spectroscopy.

Authors:  D Ben Sellem; K Elbayed; A Neuville; F-M Moussallieh; G Lang-Averous; M Piotto; J-P Bellocq; I J Namer
Journal:  J Oncol       Date:  2011-04-26       Impact factor: 4.375

Review 9.  What Is the Best Preoperative Imaging for Endometrial Cancer?

Authors:  Ingfrid S Haldorsen; Helga B Salvesen
Journal:  Curr Oncol Rep       Date:  2016-04       Impact factor: 5.075

10.  Cancer screening: a mathematical model relating secreted blood biomarker levels to tumor sizes.

Authors:  Amelie M Lutz; Juergen K Willmann; Frank V Cochran; Pritha Ray; Sanjiv S Gambhir
Journal:  PLoS Med       Date:  2008-08-19       Impact factor: 11.069

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.